Gastrointestinal Cancer News

Patients with locally advanced gastroesophageal adenocarcinoma treated with preoperative chemoradiotherapy and resection lived an average of 6 months longer when given adjuvant chemotherapy compared with observation, according to results of a retrospective study published in JAMA Oncology.

Mike Schmidt is widely considered the greatest third baseman in Major League Baseball history.

Mike Schmidt always felt a sense of invincibility as a professional athlete.

Samsung Bioepis received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Ontruzant, a biosimilar candidate to Genentech’s Herceptin, or trastuzumab, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer, according to a press release.

University of Pennsylvania announced that Ben Z. Stanger, MD, PhD, associate professor of gastroenterology in the Perelman School of Medicine, has been appointed director of the Penn Pancreatic Cancer Research Center.

Patients with hepatocellular carcinoma who started Nexavar therapy at reduced dosages had a lower total cumulative pill cost and were less likely to discontinue due to adverse effects, according to recently published data. Additionally, lower starting doses did not affect overall survival.

The FDA today approved the first biosimilar for cancer — bevacizumab-awwb — to treat patients with multiple types of cancer.

Although financial access to prescription drugs has increased in recent years, cancer survivors appeared more likely to report limited access to prescription drugs than those without a history of cancer, according to findings reported in Journal of the National Cancer Institute.

Women diagnosed with breast cancer before age 50 were twice as likely to receive a diagnosis of colorectal cancer than their older counterparts, according to the results of a meta-analysis published in Gastrointestinal Endoscopy.

Basic research in immunotherapy and precision medicine remains at the forefront of progress in cancer treatment; however, a strong bipartisan commitment from Congress is needed to continue this progress, according to the seventh annual AACR Cancer Progress Report.